Molecular biomarkers for cancer detection in blood and bodily fluids

Critical Reviews in Clinical Laboratory Sciences

Volumn 43, Issue 5-6, 2006, Pages 497-560

  Feng, Qinghua ^a   Yu, Mujun ^a   Kiviat, Nancy B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Comparative genomic hybridization array; DNA methylation; DNA microarray; Genetic mutation; Loss of heterozygosity; Mass spectrometry; Reverse transcriptase polymerase chain reaction; Two dimensional polyacrylamide gel electrophoresis

Indexed keywords

ANTIBODY; APC PROTEIN; ATM PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CYCLIN DEPENDENT KINASE 2; CYTOKINE; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; FK 506 BINDING PROTEIN; GLUTATHIONE TRANSFERASE P1; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; LACTOYLGLUTATHIONE LYASE; MICROSATELLITE DNA; MITOCHONDRIAL DNA; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P16; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RNA; TUMOR MARKER; UVOMORULIN; VASCULOTROPIN;

APC GENE; BLADDER CANCER; BLOOD ANALYSIS; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CCND2 GENE; CDH1 GENE; COLOR BLINDNESS; COMPARATIVE GENOMIC HYBRIDIZATION; DAPK1 GENE; DIAGNOSTIC APPROACH ROUTE; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; FAMILIAL CANCER; FECES ANALYSIS; GENE; GENE IDENTIFICATION; GENE MUTATION; HETEROZYGOSITY LOSS; HIN1 GENE; HUMAN; HUMAN GENOME PROJECT; LUNG CANCER; LUNX GENE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MGMT GENE; MITOCHONDRIAL DNA DISORDER; OVARY CANCER; PATIENT MONITORING; PERITONEAL FLUID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOASSAY; RARB GENE; RASSF1A GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SERIAL ANALYSIS OF GENE EXPRESSION; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS;

ANTIBODIES, NEOPLASM; BODY FLUIDS; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 33750092998     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360600922632     Document Type: Review

References (413)

1. Cancer Facts and Figures 2005, Atlanta, American Cancer Society, 2005.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10: 31-46.
4. Dorn HF, Cutler SJ. Morbidity from cancer in the United States. Public Health Monogr 1959; 73: 1-207.
5. Surveillance Epidemiology and End Results Program (online), Vol. 2005, National Cancer Institute, 2005. http://seer.cancer.gov; date of access: March, 2006.
6. Hildesheim A, Hadjimichael O, Schwartz PE, Wheeler CM, Barnes W, Lowell DM, Willett J, Schiffman M. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 1999; 180: 571-577.
7. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000; 88: 2283-2289.
8. Miller MG, Sung HY, Sawaya GF, Kearney KA, Kinney W, Hiatt RA. Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol 2003; 101: 29-37.
9. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
10. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-1637.
11. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
12. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062.
13. Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 2004; 112: 357-364.
14. Vasen HF, Tesfay E, Boonstra H, Mourits MJ, Rutgers E, Verheyen R, Oosterwijk J, Beex L. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 2005; 41: 549-554.
15. Metcalfe KA, Semple JL, Narod SA. Time to reconsider subcutaneous mastectomy for breast-cancer prevention? Lancet Oncol 2005; 6: 431-434.
16. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616-1622.
17. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy inwomenof hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005; 97: 457-467.
18. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1: 157-162.
19. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
20. Goessl C, Muller M, Straub B, Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol II 2002; 41: 668-676.
21. Cheng KC, Loeb LA. Genomic stability and instability: a working paradigm. Curr Top Microbiol Immunol 1997; 221: 5-18.
22. Jackson AL, Loeb LA. On the origin of multiple mutations in human cancers. Semin Cancer Biol 1998; 8: 421-429.
23. Jakupciak JP, Wang W, Markowitz ME, Ally D, Coble M, Srivastava S, Maitra A, Barker PE, Sidransky D, O'Connell CD. Mitochondrial DNA as a cancer biomarker. J Mol Diagn 2005; 7: 258-267.
24. [23a] Kagan J, Srivastava S. Mitochondria as a target for early detection and diagnosis of cancer. Crit Rev Clin Lab Sci 2005; 42: 453-472.
25. James LA. Comparative genomic hybridization as a tool in tumour cytogenetics. J Pathol 1999; 187: 385-395.
26. Albertson DG, Pinkel D. Genomic microarrays in human genetic disease and cancer. Hum Mol Genet 2003; 12 Spec No 2: R145-152.
27. Gebhart E. Comparative genomic hybridization (CGH): ten years of substantial progress in human solid tumor molecular cytogenetics. Cytogenet Genome Res 2004; 104: 352-358.
28. Oostlander AE, Meijer GA, Ylstra B. Microarray-based comparative genomic hybridization and its applications in human genetics. Clin Genet 2004; 66: 488-495.
29. Mantripragada KK, Buckley PG, de Stahl TD, Dumanski JP. Genomic microarrays in the spotlight. Trends Genet 2004; 20: 87-94.
30. Shih Ie M, Wang TL. Apply innovative technologies to explore cancer genome. Curr Opin Oncol 2005; 17: 33-38.
31. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004; 95: 559-563.
32. Lucito R, West J, Reiner A, Alexander J, Esposito D, Mishra B, Powers S, Norton L, Wigler M. Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. Genome Res 2000; 10: 1726-1736.
33. Lapierre JM, Tachdjian G. Detection of chromosomal abnormalities by comparative genomic hybridization. Curr Opin Obstet Gynecol 2005; 17: 171-177.
34. Anno S, Kudo S, Hamasaki K, Matsumura K, Yamamoto T, Ogata K. Techniques of SNP genotyping and remote sensing applied for elucidation of the contribution of polygene and environmental factors to inter-individual variation in skin pigmentation phenotype. J Physiol Anthropol Appl Human Sci 2005; 24: 483-486.
35. Kwok PY. Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet 2001; 2: 235-258.
36. Maris JM, Hii G, Gelfand CA, Varde S, White PS, Rappaport E, Surrey S, Fortina P. Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Res 2005; 15: 1168-1176.
37. Olivier M. The Invader assay for SNP genotyping. Mutat Res 2005; 573: 103-110.
38. Tost J, Gut IG. Genotyping single nucleotide polymorphisms by mass spectrometry. Mass Spectrom Rev 2002; 21: 388-418.
39. Sauer S, Gut IG. Genotyping single-nucleotide polymorphisms by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 782: 73-87.
40. Gut IG. DNA analysis by MALDI-TOF mass spectrometry. Hum Mutat 2004; 23: 437-441.
41. Tost J, Gut IG. Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications. Clin Biochem 2005; 38: 335-350.
42. Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat 2002; 19: 479-485.
43. Tuziak T, Jeong J, Majewski T, Kim MS, Steinberg J, Wang Z, Yoon DS, Kuang TC, Baggerly K, Johnston, D, Czerniak B. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis. Lab Invest 2005; 85: 689-701.
44. Shen R, Fan JB, Campbell D, Chang W, Chen J, Doucet D, Yeakley J, Bibikova M, Wickham Garcia E, McBride C, Steemers F, Garcia F, Kermani BG, Gunderson K, Oliphant A. High-throughput SNP genotyping on universal bead arrays. Mutat Res 2005; 573: 70-82.
45. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
46. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266.
47. [45a] Verma M, Maruvada P, Srivastava S. Epigenetics and cancer. Crit Rev Clin Lab Sci 2004; 41: 585-607.
48. Leonhardt H, Cardoso MC. DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem Suppl 2000; 35(Suppl): 78-83.
49. Warnecke PM, Bestor TH. Cytosine methylation and human cancer. Curr Opin Oncol 2000; 12: 68-73.
50. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196: 1-7.
51. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28: E32.
52. Rauch T, Pfeifer GP. Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab Invest 2005; 85: 1172-1180.
53. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141-149.
54. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 3735-3742.
55. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002; 2: 485-495.
56. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65: 4218-4227.
57. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 114-123.
58. Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004; 64: 3871-3877.
59. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R. Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 2005; 25: 3923-3933.
60. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 1991; 117: 144-150.
61. Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, Yachi A. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer 1993; 54: 614-618.
62. Wang F, McKeehan WL. Insulin-like growth factor-1 messenger RNA isoforms in rat prostate and prostate tumors. In Vitro Cell Dev Biol Anim 1996; 32: 265-268.
63. Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, Hood L, Wang K. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999; 96: 3114-3119.
64. Khosravi J, Diamandi A, Mistry J, Scorilas A. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 2001; 86: 694-699.
65. Figueroa JA, De Raad S, Speights VO, Rinehart JJ. Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters. Cancer Invest 2001; 19: 28-34.
66. Bermont L, Algros MP, Baron MH, Adessi GL. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma. Breast Cancer Res Treat 2000; 63: 163-169.
67. Kurebayashi J. Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 2001; 8: 45-51.
68. Kandel R, Zhu XL, Li SQ, Rohan T. Cyclin D1 protein overexpression and gene amplification in benign breast tissue and breast cancer risk. Eur J Cancer Prev 2001; 10: 43-51.
69. Oh YL, Choi JS, Song SY, Ko YH, Han BK, Nam SJ, Yang JH. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 2001; 51: 94-99.
70. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer 2000; 7: 143-164.
71. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95: 92-95.
72. Miller M, Smith D, Windsor A, Kessling A. Survivin gene expression and prognosis in recurrent colorectal cancer. Gut 2001; 48: 137-138.
73. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001; 163: 109-116.
74. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285: 324-328.
75. Lipshutz RJ, Morris D, Chee M, Hubbell E, Kozal MJ, Shah N, Shen N, Yang R, Fodor SP. Using oligonucleotide probe arrays to access genetic diversity. Biotechniques 1995; 19: 442-447.
76. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995; 270: 467-470.
77. Nguyen C, Rocha D, Granjeaud S, Baldit M, Bernard K, Naquet P, Jordan BR. Differential gene expression in the murine thymus assayed by quantitative hybridization of arrayed cDNA clones. Genomics 1995; 29: 207-216.
78. Yamamoto M, Wakatsuki T, Hada A, Ryo A. Use of serial analysis of gene expression (SAGE) technology. J Immunol Methods 2001; 250: 45-66.
79. Riggins GJ. Using Serial Analysis of Gene Expression to identify tumor markers and antigens. Dis Markers 2001; 17: 41-48.
80. Hermeking H. Serial analysis of gene expression and cancer. Curr Opin Oncol 2003; 15: 44-49.
81. Boheler KR, Stern MD. The new role of SAGE in gene discovery. Trends Biotechnol 2003; 21: 55-57; discussion 57-58.
82. Tuteja R, Tuteja N. Serial analysis of gene expression (SAGE): application in cancer research. Med Sci Monit 2004; 10: RA132-140.
83. Ugrinska A, Bombardieri E, Stokkel MP, Crippa F, Pauwels EK. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer. Q J Nucl Med 2002; 46: 88-104.
84. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-826.
85. Bast RC, Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-1878.
86. Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L, Smith R. Perspective: a program to improve protein biomarker discovery for cancer. J Proteome Res 2005; 4: 1104-1109.
87. Pang S, Smith J, Onley D, Reeve J, Walker M, Foy CA comparability study of the emerging protein array platforms with established ELISA procedures. J Immunol Methods 2005; 302: 1-12.
88. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720-1730.
89. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-867.
90. Somiari RI, Somiari S, Russell S, Shriver CD. Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815: 215-225.
91. Lee SW, Lee KI, Kim JY. Revealing urologic diseases by proteomic techniques. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815: 203-213.
92. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow LP. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 2005; 4: 2062-2069.
93. Xiong XD, Xu LY, Shen ZY, Cai WJ, Luo JM, Han YL, Li EM. Identification of differentially expressed proteins between human esophageal immortalized and carcinomatous cell lines by two-dimensional electrophoresis and MALDI-TOF-mass spectrometry. World J Gastroenterol 2002; 8: 777-781.
94. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002; 8: 2298-2305.
95. Seike M, Kondo T, Fujii K, Okano T, Yamada T, Matsuno Y, Gemma A, Kudoh S, Hirohashi S. Proteomic signatures for histological types of lung cancer. Proteomics 2005; 5: 2939-2948.
96. Gade D, Thiermann J, Markowsky D, Rabus R. Evaluation of two-dimensional difference gel electrophoresis for protein profiling. Soluble proteins of the marine bacterium Pirellula sp. strain 1. J Mol Microbiol Biotechnol 2003; 5: 240-251.
97. Marouga R, David S, Hawkins E. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005; 382: 669-678.
98. Stevens EV, Posadas EM, Davidson B, Kohn EC. Proteomics in cancer. Ann Oncol 2004; 15(Suppl 4): iv,167-171.
99. Rodland KD. Proteomics and cancer diagnosis: the potential of mass spectrometry. Clin Biochem 2004; 37: 579-583.
100. Posadas EM, Simpkins F, Liotta LA, MacDonald C, Kohn EC. Proteomic analysis for the early detection and rational treatment of cancer-realistic hope? Ann Oncol 2005; 16: 16-22.
101. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52: 6380-6384.
102. Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996; 2: 1767-1775.
103. Fernandez Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett 2005; 230: 187-198.
104. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter G, Old LJ, Knuth A. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999; 84: 506-510.
105. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000; 62: 245-252.
106. Coomber DW. Panning of antibody phage-display libraries. Standard protocols. Methods Mol Biol 2002; 178: 133-145.
107. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-1989.
108. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Espina V, Munson PJ, Petricoin E 3rd, Liotta LA, Weinstein JN. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 2003; 100: 14229-14234.
109. Madoz-Gurpide J, Wang H, Misek DE, Brichory F, Hanash SM. Protein based microarrays: a tool for probing the proteome of cancer cells and tissues. Proteomics 2001; 1: 1279-1287.
110. Ramachandran N, Hainsworth E, Bhullar B, Eisenstein S, Rosen B, Lau AY, Walter JC, LaBaer J. Self-assembling protein microarrays. Science 2004; 305: 86-90.
111. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
112. Rossi A, Maione P, Colantuoni G, Gaizo FD, Guerriero C, Nicolella D, Ferrara C, Gridelli C. Screening for lung cancer: New horizons? Crit Rev Oncol Hematol 2005; 56: 311-320.
113. Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999; 5: 2689-2692.
114. Cuda G, Gallelli A, Nistico A, Tassone P, Barbieri V, Tagliaferri PS, Costanzo FS, Tranfa CM, Venuta S. Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients: a tool for early diagnosis? Lung Cancer 2000; 30: 211-214.
115. Liloglou T, Maloney P, Xinarianos G, Hulbert M, Walshaw MJ, Gosney JR, Turnbull L, Field JK. Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. Cancer Res 2001; 61: 1624-1628.
116. Pan H, Califano J, Ponte JF, Russo AL, Cheng KH, Thiagalingam A, Nemani P, Sidransky D, Thiagalingam S. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 2005; 65: 1664-1669.
117. Grepmeier U, Dietmaier W, Merk J, Wild PJ, Obermann EC, Pfeifer M, Hofstaedter F, Hartmann A, Woenckhaus M. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. Int J Oncol 2005; 27: 481-488.
118. Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, Hong WK, Mao L. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res 2000; 6: 559-565.
119. Haga Y, Hiroshima K, Iyoda A, Kohno H, Shibuya K, Iizasa T, Fujisawa T, Ohwada H. Frequency of loss of heterozygosity at 3 p, 9 p, 13 q, and 17 p is related to proliferative activity in smokers with stage I non-small cell lung cancer. Thorac Cardiovasc Surg 2005; 53: 114-117.
120. Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, Roz L, Pelosi G, Goldstraw P, Sozzi G, Pastorino U. Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer 2004; 108: 91-96.
121. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000; 287: 2017-2019.
122. Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M, Jeronimo C, Jordan RC, Nicol T, Koch WM, Schoenberg M, Mazzarelli P, Fazio VM, Sidransky D. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res 2001; 61: 7015-7019.
123. Jin XJ, Zhang JJ, Song Y, Gao YN, Cheng SJ. [Mitochondrial DNA mutations in lung cancer]. Ai Zheng 2002; 21: 715-718.
124. Suzuki M, Toyooka S, Miyajima K, Iizasa T, Fujisawa T, Bekele NB, Gazdar AF. Alterations in the mitochondrial displacement loop in lung cancers. Clin Cancer Res 2003; 9: 5636-5641.
125. Matsuyama W, Nakagawa M, Wakimoto J, Hirotsu Y, Kawabata M, Osame M. Mitochondrial DNA mutation correlates with stage progression and prognosis in non-small cell lung cancer. Hum Mutat 2003; 21: 441-443.
126. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21: 5450-5461.
127. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4: 707-717.
128. Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, de Aguirre I, Sanchez JM, Manzano JL, Margeli M, Sanchez JJ, Astudillo J, Taron M, Rosell R. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003; 193: 207-216.
129. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H, Tanimoto M. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005; 11: 1219-1225.
130. An Q, Liu Y, Gao Y, Huang J, Fong X, Li L, Zhang D, Cheng S. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett 2002; 188: 109-114.
131. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70.
132. Grote HJ, Schmiemann V, Geddert H, Bocking A, Kappes R, Gabbert HE, Sarbia M. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 2006; 108: 129-134.
133. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles J, Danenberg PV, Yang S, Sidransky D. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002; 62: 371-375.
134. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-5958.
135. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA, Byers T. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006; 66: 3338-3344.
136. Cirincione R, Lintas C, Conte D, Mariani L, Roz L, Vignola AM, Pastorino U, Sozzi G. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 2006; 118: 1248-1253.
137. Russo AL, Thiagalingam A, Pan H, Califano J, Cheng KH, Ponte JF, Chinnappan D, Nemani P, Sidransky D, Thiagalingam S. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 2005; 11: 2466-2470.
138. Petty RD, Nicolson MC, Kerr KM, Collie-Duguid E, Murray GI. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res 2004; 10: 3237-3248.
139. Iwao K, Watanabe T, Fujiwara Y, Takami K, Kodama K, Higashiyama M, Yokouchi H, Ozaki K, Monden M, Tanigami A. Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Int J Cancer 2001; 91: 433-437.
140. Hibi K, Liu Q, Beaudry GA, Madden SL, Westra WH, Wehage SL, Yang SC, Heitmiller RF, Bertelsen AH, Sidransky D, Jen J. Serial analysis of gene expression in non-small cell lung cancer. Cancer Res 1998; 58: 5690-5694.
141. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 1999; 155: 711-715.
142. Sasaki H, Yukiue H, Moriyama S, Kobayashi Y, Nakashima Y, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. Jpn J Clin Oncol 2001; 31: 532-535.
143. Mitas M, Hoover L, Silvestri G, Reed C, Green M, Turrisi AT, Sherman C, Mikhitarian K, Cole DJ, Block MI. Gillanders WE. Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn 2003; 5: 237-242.
144. Li Y, Dong X, Yin Y, Su Y, Xu Q, Zhang Y, Pang X, Zhang Y, Chen W. BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia 2005; 7: 1073-1080.
145. Matsunaga H, Hangai N, Aso Y, Okano K, Kawamura M, Kobayashi K, Kambara H, Hoger JH, Mitsuhashi M. Application of differential display to identify genes for lung cancer detection in peripheral blood. Int J Cancer 2002; 100: 592-599.
146. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone, DP. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003; 362: 433-439.
147. Chanin TD, Merrick DT, Franklin WA, Hirsch FR. Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present. Curr Opin Pulm Med 2004; 10: 242-247.
148. Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G, Domont GB. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol 2005; 5: 31-38.
149. Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald MC, Bepler G, Patz EF Jr. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004; 46: 313-323.
150. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001; 61: 7908-7912.
151. Xiao XY, Tang Y, Wei XP, He DC. A preliminary analysis of non-small cell lung cancer biomarkers in serum. Biomed Environ Sci 2003; 16: 140-148.
152. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005; 293: 1245-1256.
153. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869-1874.
154. Shannon C, Smith IE. Breast cancer in adolescents and young women. Eur J Cancer 2003; 39: 2632-2642.
155. Klein PM, Lawrence JA. Lavage and nipple aspiration of breast ductal fluids: a source of biomarkers for environmental mutagenesis. Environ Mol Mutagen 2002; 39: 127-133.
156. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988; 319: 1681-1692.
157. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451-1467.
158. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
159. Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer 2003; 97: 880-886.
160. Baum M. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: Where are we now? Eur J Cancer 2005; 41: 1667-1677.
161. Lewis F, Jackson P, Lane S, Coast G, Hanby AM. Testing for HER2 in breast cancer. Histopathology 2004; 45: 207-217.
162. Stroun M, Anker P, Lyautey J, Lederrey C. Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987; 23: 707-712.
163. Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, Harris AL, Wainscoat JS. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004; 90: 1211-1215.
164. Shao ZM, Nguyen M. Tumor-specific DNA in plasma of breast cancer patients. Anticancer Drugs 2002; 13: 353-357.
165. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareno E, Colas A, Espana P, Bonilla F. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 2002; 8: 3761-3766.
166. Dang RK, Anthony RS, Craig JI, Leonard RC, Parker AC. Limitations of the
167. Chen X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub E, Stroun M, Anker P. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999; 5: 2297-2303.
168. Schwarzenbach H, Muller V, Stahmann N, Pantel K. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann NY Acad Sci 2004; 1022: 25-32.
169. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, Espana P, Bonilla F. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999; 59: 3251-3256.
170. Richard SM, Bailliet G, Paez GL, Bianchi MS, Peltomaki P, Bianchi NO. Nuclear and mitochondrial genome instability in human breast cancer. Cancer Res 2000; 60: 4231-4237.
171. Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, Pandit S, Spencer M, Rabitti C, Fazio VM, Sidransky D. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res 2001; 61: 7623-7626.
172. Tan DJ, Bai RK, Wong LJ. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res 2002; 62: 972-976.
173. Parrella P, Seripa D, Matera MG, Rabitti C, Rinaldi M, Mazzarelli P, Gravina C, Gallucci M, Altomare V, Flammia G, Casalino B, Benedetti-Panici PL, Fazio VM. Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Lett 2003; 190: 73-77.
174. Zhu W, Qin W, Sauter ER. Large-scale mitochondrial DNA deletion mutations and nuclear genome instability in human breast cancer. Cancer Detect Prev 2004; 28: 119-126.
175. Zhu W, Qin W, Bradley P, Wessel A, Puckett CL, Sauter ER. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis 2005; 26: 145-152.
176. Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M, Motoyama T. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001; 85: 69-73.
177. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001; 61: 2782-2787.
178. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229.
179. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107: 970-975.
180. Silva JM, Dominguez G, Villanueva MJ, Gonzalez R, Garcia JM, Corbacho C, Provencio M, Espana P, Bonilla F. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br J Cancer 1999; 80: 1262-1264.
181. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004; 10: 6189-6193.
182. [179a] Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Trink B, Kiviat NB, Sidransky D. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006; 24: 4262-4269.
183. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001; 357: 1335-1336.
184. Lee A, Kim Y, Han K, Kang CS, Jeon HM, Shim SI. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast. Arch Pathol Lab Med 2004; 128: 1251-1256.
185. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, Sukumar S. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004; 64: 4442-4452.
186. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
187. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
188. Murphy N, Millar E, Lee CS. Gene expression profiling in breast cancer: towards individualising patient management. Pathology 2005; 37: 271-277.
189. van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 2005; 23: 1631-1635.
190. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
191. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R, Friend SH. Expression profiling predicts outcome in breast cancer. Breast Cancer Res 2003; 5: 57-58.
192. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738-3743.
193. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65: 4059-4066.
194. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005; 11: 481-483.
195. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
196. Kahn HJ, Presta A, Yang LY, Blondal J, Trudeau M, Lickley L, Holloway C, McCready DR, Maclean D, Marks A. Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res Treat 2004; 86: 237-247.
197. Cruz I, Ciudad J, Cruz JJ, Ramos M, Gomez-Alonso A, Adansa JC, Rodriguez C, Orfao A. Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. Am J Clin Pathol 2005; 123: 66-74.
198. Ring AE, Zabaglo L, Ormerod MG, Smith IE, Dowsett M. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 2005; 92: 906-912.
199. Bae JW, Choi KH, Kim HG, Park SH. The detection of circulating breast cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. J Korean Med Sci 2000; 15: 194-198.
200. Masuda TA, Kataoka A, Ohno S, Murakami S, Mimori K, Utsunomiya T, Inoue H, Tsutsui S, Kinoshita J, Masuda N, Moriyama N, Mori M. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. Int J Oncol 2005; 26: 721-730.
201. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005; 11: 3678-3685.
202. Zehentner BK, Deme A, Toure P, Hawes SE, Brooks L, Feng Q, Hayes DC, Persing DH, Critichlow CW, Houghton RL, Kiviat NB. Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. Clin Chem 2004; 50: 2069-2076.
203. Fabisiewicz A, Kulik J, Kober P, Brewczynska E, Pienkowski T, Siedlecki JA. Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay. Acta Biochim Pol 2004; 51: 747-755.
204. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC, Lingle WL. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res 2005; 11: 3722-3732.
205. Hager G, Cacsire-Castillo Tong D, Schiebel I, Rezniczek GA, Watrowski R, Speiser P, Zeillinger R. The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection. Gynecol Oncol 2005; 98: 211-216.
206. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996; 56: 860-865.
207. Fleming TP, Watson MA. Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann NY Acad Sci 2000; 923: 78-89.
208. Carter D, Douglass JF, Cornellison CD, Retter MW, Johnson JC, Bennington AA, Fleming TP, Reed SG, Houghton RL, Diamond DL, Vedvick TS. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 2002; 41: 6714-6722.
209. Fanger GR, Houghton RL, Retter MW, Hendrickson RC, Babcook J, Dillon DC, Durham MD, Reynolds LD, Johnson JC, Carter D, Fleming TP, Roche PC, Persing DH, Reed SG. Detection of mammaglobin in the sera of patients with breast cancer. Tumour Biol 2002; 23: 212-221.
210. Hudelist G, Pacher-Zavisin M, Singer CF, Holper T, Kubista E, Schreiber M, Manavi M, Bilban M, Czerwenka K. Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res Treat 2004; 86: 281-291.
211. Kuerer HM, Coombes KR, Chen JN, Xiao L, Clarke C, Fritsche H, Krishnamurthy S, Marcy S, Hung MC, Hunt KK. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery 2004; 136: 1061-1069.
212. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 2005; 89: 149-157.
213. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, Perry RR, Wright GL Jr, Semmes OJ. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4: 203-209.
214. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48: 1296-1304.
215. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 2002; 86: 1440-1443.
216. Sjovall K, Nilsson B. Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 2002; 85: 175-178.
217. Skates S, Troiano R, Knapp RC. Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003; 13: 693-696.
218. Urban N, McIntosh MW, Andersen M, Karlan BY. Ovarian cancer screening. Hematol Oncol Clin North Am 2003; 17: 989-1005, ix.
219. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 355-366.
220. Nicosia SV, Bai W, Cheng JQ, Coppola D, Kruk PA. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 2003; 17: 927-943.
221. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003; 202: 97-99.
222. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-7681.
223. Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T, Kushima M. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer 2004; 14: 459-464.
224. Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, King MC. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol 2005; 193: 662-667.
225. Fabjani G, Kriegshaeuser G, Schuetz A, Prix L, Zeillinger R. Biochip for K-ras mutation screening in ovarian cancer. Clin Chem 2005; 51: 784-787.
226. Zborovskaya I, Gasparian A, Karseladze A, Elcheva I, Trofimova E, Driouch K, Trassard M, Tatosyan A, Lidereau R. Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity. Int J Cancer 1999; 82: 822-826.
227. Hansen LL, Jensen LL, Dimitrakakis C, Michalas S, Gilbert F, Barber HR, Overgaard J, Arzimanoglou II. Allelic imbalance in selected chromosomal regions in ovarian cancer. Cancer Genet Cytogenet 2002; 139: 1-8.
228. Manderson EN, Presneau N, Provencher D, Mes-Masson AM, Tonin PN. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Mol Carcinog 2002; 34: 78-90.
229. Byrom J, Mudaliar V, Redman CW, Jones P, Strange RC, Hoban PR. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors. Int J Oncol 2004; 24: 1271-1277.
230. Bozzetti C, Bortesi B, Merisio C. Loss of heterozygosity (LOH) in ovarian cancer. Int J Gynaecol Obstet 2004; 85: 294-295.
231. Wang N. Cytogenetics and molecular genetics of ovarian cancer. Am J Med Genet 2002; 115: 157-163.
232. Lambros MB, Fiegler H, Jones A, Gorman P, Roylance RR, Carter NP, Tomlinson IP. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J Pathol 2005; 205: 29-40.
233. Parrella P, Zangen R, Sidransky D, Nicol T. Molecular analysis of peritoneal fluid in ovarian cancer patients. Mod Pathol 2003; 16: 636-640.
234. Tu H, Gao HF, Fu SL, Chen H. Quantitative analysis of circulating DNA in serum of cancer patients. Zhonghua Zhong Liu Za Zhi 2004; 26: 606-608.
235. Hickey KP, Boyle KP, Jepps HM, Andrew AC, Buxton EJ, Burns PA. Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer 1999; 80: 1803-1808.
236. Liu VW, Shi HH, Cheung AN, Chiu PM, Leung TW, Nagley P, Wong LC, Ngan HY. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res 2001; 61: 5998-6001.
237. Shi HH, Vincent L, Hextan N, Yang XY. Mutations in the D-loop region of mitochondrial DNA in ovarian tumors. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2002; 24: 170-173.
238. Li HX, Zhong S, Li CH. Study on the mitochondrion DNA mutation in tumor tissues of gynecologic oncology patients. Zhonghua Fu Chan Ke Za Zhi 2003; 38: 290-293.
239. Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 2001; 158: 1121-1127.
240. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002; 8: 3324-3331.
241. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004; 64: 6476-6481.
242. Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME. Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol 2002; 20: 982-986.
243. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41: 265-312.
244. Yousef GM, Diamandis EP. An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. Clin Biochem 2003; 36: 443-452.
245. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005; 224: 1-22.
246. Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L, Mulligan J. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999; 229: 101-108.
247. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999; 238: 375-385.
248. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 2001; 30: 670-675.
249. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93: 1458-1464.
250. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004; 95: 9-15.
251. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267-277.
252. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002; 2: 76-84.
253. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 2904-2911.
254. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-5890.
255. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 7677-7682.
256. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995; 59: 111-116.
257. Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC Jr. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22: 4059-4066.
258. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 981-987.
259. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006; 66: 1181-1190.
260. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-105.
261. Eguchi S, Kohara N, Komuta K, Kanematsu T. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996; 77: 1707-1710.
262. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, Hamilton SR, Boynton K, Kinzler KW, Vogelstein B. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346: 311-320.
263. Koshiji M, Yonekura Y, Saito T, Yoshioka K. Microsatellite analysis of fecal DNA for colorectal cancer detection. J Surg Oncol 2002; 80: 34-40.
264. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003; 49: 1058-1065.
265. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-1227.
266. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, Hibi K, Goodman SN, D'Allessio M, Paty P, Hamilton SR, Sidransky D, Barany F, Levin B, Shuber A, Kinzler KW, Vogelstein B, Jen J. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93: 858-865.
267. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 47-53.
268. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003; 1: 377-383.
269. Brand RE, Ross ME, Shuber AP. Reproducibility of a multitarget stool-based DNA assay for colorectal cancer detection. Am J Gastroenterol 2004; 99: 1338-1341.
270. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005; 128: 192-206.
271. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002; 315: 157-168.
272. Matsushita H, Matsumura Y, Moriya Y, Akasu T, Fujita S, Yamamoto S, Onouchi S, Saito N, Sugito M, Ito M, Kozu T, Minowa T, Nomura S, Tsunoda H, Kakizoe T. A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology 2005; 129: 1918-1927.
273. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, Muhlthaler M, Ofner D, Margreiter R, Widschwendter M. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004; 363: 1283-1285.
274. Belshaw NJ, Elliott GO, Williams EA, Bradburn DM, Mills SJ, Mathers JC, Johnson IT. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 1495-1501.
275. Leung WK, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Lee JF, Sung JJ. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem 2004; 50: 2179-2182.
276. Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Goke B, Lamerz R, Kolligs FT. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 142-149.
277. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 2005; 11: 1203-1209.
278. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97: 1124-1132.
279. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-521.
280. Xin B, Platzer P, Fink SP, Reese L, Nosrati A, Willson JK, Wilson K, Markowitz S. Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia. Oncogene 2005; 24: 724-731.
281. Davidson LA, Lupton JR, Miskovsky E, Fields AP, Chapkin RS. Quantification of human intestinal gene expression profiles using exfoliated colonocytes: a pilot study. Biomarkers 2003; 8: 51-61.
282. Ahmed FE, Vos P. Molecular markers for human colon cancer in stool and blood identified by RT-PCR. Anticancer Res 2004; 24: 4127-4134.
283. Ahmed FE, James SI, Lysle DT, Dobbs LJ Jr, Johnke RM, Flake G, Stockton P, Sinar DR, Naziri W, Evans MJ, Kovacs CJ, Allison RR. Improved methods for extracting RNA from exfoliated human colonocytes in stool and RT-PCR analysis. Dig Dis Sci 2004; 49: 1889-1898.
284. Guller U, Zajac P, Schnider A, Bosch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-775.
285. Miura M, Ichikawa Y, Tanaka K, Kamiyama M, Hamaguchi Y, Ishikawa T, Yamaguchi S, Togo S, Ike H, Ooki S, Shimada H. Real-time PCR (TaqMan PCR) quantification of carcinoembryonic antigen (CEA) mRNA in the peripheral blood of colorectal cancer patients. Anticancer Res 2003; 23: 1271-1276.
286. Karanikiotis C, Skiadas I, Karina M, Georgakopoulou S, Georgakopoulos E, Fountzilas G. A novel chromatographic method for Ep-CAM mRNA detection in peripheral blood and bone marrow of patients with metastatic colorectal cancer. Anticancer Res 2005; 25: 319-323.
287. Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW, Lai BS, Lee KC, Lo YM. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res 2004; 10: 1613-1617.
288. Lledo SM, Garcia-Granero E, Dasi F, Ripoli R, Garcia SA, Cervantes A, Alino SF. Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Colorectal Dis 2004; 6: 236-242.
289. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23: 338-351.
290. Krieg RC, Fogt F, Braunschweig T, Herrmann PC, Wollscheidt V, Wellmann A. ProteinChip Array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range. Anticancer Res 2004; 24: 1791-1796.
291. Melle C, Osterloh D, Ernst G, Schimmel B, Bleul A, von Eggeling F. Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. Int J Mol Med 2005; 16: 11-17.
292. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004; 4: 793-811.
293. Albrethsen J, Bogebo R, Gammeltoft S, Olsen J, Winther B. Raskov H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005; 5: 8.
294. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 2004; 10: 8380-8385.
295. Seraglia R, Ragazzi E, Vogliardi S, Allegri G, Pucciarelli S, Agostini M, Lise M, Nitti D, Urso ED, Traldi, P. Search of plasma markers for colorectal cancer by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 2005; 40: 123-126.
296. Schwartz K, Deschere B, Xu, J. Screening for prostate cancer: who and how often? J Fam Pract 2005; 54: 586-596.
297. Henrique R, Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004; 46: 660-669.
298. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004; 91: 540-552.
299. Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, Sidransky D. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002; 60: 1131-1135.
300. Goessl C, Muller M, Heicappell R, Krause H, Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann NY Acad Sci 2001; 945: 51-58.
301. Tchou JC, Lin X, Freije D, Isaacs WB, Brooks JD, Rashid A, De Marzo AM, Kanai Y, Hirohashi S, Nelson, WG. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol 2000; 16: 663-676.
302. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998; 58: 4515-4518.
303. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202: 233-240.
304. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005; 65: 713-718.
305. Patel K, Whelan PJ, Prescott S, Brownhill SC, Johnston CF, Selby PJ, Burchill SA. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer. Clin Cancer Res 2004; 10: 7511-7519.
306. Schamhart DH, Maiazza R, Kurth KH. Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology (review). Int J Oncol 2005; 26: 565-577.
307. Chu DC, Chuang CK, Liou YF, Tzou RD, Lee HC, Sun CF. The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma. Ann NY Acad Sci 2004; 1022: 157-162.
308. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs, WB. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-5979.
309. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, Masse B, Piche L, Chypre C. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-315.
310. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 2004; 46: 182-186.
311. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG. Are multiple markers the future of prostate cancer diagnostics? Clin Biochem 2004; 37: 519-528.
312. Paul B, Dhir R, Landsittel D, Hitchens MR, Getzenberg RH. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 2005; 65: 4097-4100.
313. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161: 182-187.
314. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004; 10: 3943-3953.
315. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL, Jr. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from
316. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662-1670.
317. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. J Urol 2004; 172: 1501-1503.
318. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004; 96: 834-843.
319. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar M, Gleave ME, Vielkind J. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 2004; 64: 5929-5933.
320. Banez LL, Srivastava S, Moul JW. Proteomics in prostate cancer. Curr Opin Urol 2005; 15: 151-156.
321. Wright ME, Han DK, Aebersold R. Mass spectrometry-based expression profiling of clinical prostate cancer. Mol Cell Proteomics 2005; 4: 545-554.
322. Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF, 3rd. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004; 172: 1302-1305.
323. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 1224-1235.
324. Eissa S, Kassim S, El-Ahmady O. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol 2003; 15: 395-403.
325. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003; 169: 1975-1982.
326. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 2004; 340: 57-65.
327. Sanchez-Carbayo M. Recent advances in bladder cancer diagnostics. Clin Biochem 2004; 37: 562-571.
328. Quek ML, Sanderson K, Daneshmand S, Stein JP. New molecular markers for bladder cancer detection. Curr Opin Urol 2004; 14: 259-264.
329. Hussain SA, James ND. Molecular markers in bladder cancer. Semin Radiat Oncol 2005; 15: 3-9.
330. Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol 2004; 14: 277-286.
331. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706-709.
332. Yamada H, Kakehi Y, Okuno H, Yoshida O. Detection of tumor-derived DNA in exfoliated cells of urine sediments with a novel quantitative PCR method based on allele-specific PCR. Cancer Lett 1998; 126: 111-118.
333. Schlichtholz B, Presler M, Matuszewski M. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast. Carcinogenesis 2004; 25: 2319-2323.
334. Linn JF, Lango M, Halachmi S, Schoenberg MP, Sidransky D. Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer 1997; 74: 625-629.
335. Mourah S, Cussenot O, Vimont V, Desgrandchamps F, Teillac P, Cochant-Priollet B, Le Duc A, Fiet J, Soliman H. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer 1998; 79: 629-633.
336. Seripa D, Parrella P, Gallucci M, Gravina C, Papa S, Fortunato P, Alcini A, Flammia G, Lazzari M, Fazio, VM. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int J Cancer 2001; 95: 364-369.
337. Neves M, Ciofu C, Larousserie F, Fleury J, Sibony M, Flahault A, Soubrier F, Gattegno B. Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection. J Urol 2002; 167: 1276-1281.
338. Berger AP, Parson W, Stenzl A, Steiner H, Bartsch G, Klocker H. Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue. Eur Urol 2002; 41: 532-539.
339. Utting M, Werner W, Dahse R, Schubert J, Junker K. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res 2002; 8: 35-40.
340. Bartoletti R, Dal Canto M, Cai T, Piazzini M, Travaglini F, Gavazzi A, Rizzo M. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Oncol Rep 2005; 13: 531-537.
341. Molina Burgos R, Millan Salvador JM, Oltra Soler JS, Jimenez Cruz JF. Microsatellite analysis in exfoliated cells from urinary sediment. Its utility for the detection of bladder cancer. Comparison with urinary cytology. Actas Urol Esp 2003; 27: 618-628.
342. Utting M, Werner W, Muller G, Schubert J, Junker K. A possible noninvasive method for the detection of bladder cancer in patients: microsatellite analysis of free DNA in urine and blood. Ann NY Acad Sci 2001; 945: 31-35.
343. Christensen M, Wolf H, Orntoft TF. Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. Int J Cancer 2000; 85: 614-617.
344. Hoque MO, Lee J, Begum S, Yamashita K, Engles JM, Schoenberg M, Westra WH, Sidransky D. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res 2003; 63: 5723-5726.
345. Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 2003; 63: 2216-2222.
346. Chen GF, Chan FL, Hong BF, Chan LW, Chan PS. Mitochondrial DNA mutations in chemical carcinogen-induced rat bladder and human bladder cancer. Oncol Rep 2004; 12: 463-472.
347. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002; 8: 464-470.
348. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004; 10: 1887-1893.
349. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, Toma MI, Huland H, Yoo C, Tsai YC, Nichols PW, Bochner BH, Jones PA, Liang G. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004; 10: 7457-7465.
350. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto, JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006; 25: 1984-1988.
351. Eissa S, Kenawy G, Swellam M, El-Fadle AA, Abd El-Aal AA, El-Ahmady, O. Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma. Clin Biochem 2004; 37: 803-810.
352. Eissa S, Kassim SK, Labib RA, El-Khouly IM, Ghaffer TM, Sadek M, Razek OA, El-Ahmady O. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 2005; 103: 1356-1362.
353. Siracusano S, Niccolini B, Knez R, Tiberio A, Benedetti E, Bonin S, Ciciliato S, Pappagallo GL, Belgrano E, Stanta G. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine. Eur Urol 2005; 47: 327-333.
354. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003; 163: 505-516.
355. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer 2003; 89: 2172-2177.
356. Celis JE, Ostergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, Andersen I, Hein B, Wolf H, Orntoft TF, Rasmussen HH. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996; 56: 4782-4790.
357. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol 1996; 155: 2113-2119.
358. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res 1997; 57: 4111-4117.
359. Celis JE, Ostergaard M, Rasmussen HH, Gromov P, Gromova I, Varmark H, Palsdottir H, Magnusson N, Andersen I, Basse B, Lauridsen JB, Ratz G, Wolf H, Orntoft TF, Celis P, Celis A. A comprehensive protein resource for the study of bladder cancer: http://biobase.dk/cgi-bin/celis. Electrophoresis 1999; 20: 300-309.
360. Ostergaard M, Wolf H, Orntoft TF, Celis, JE. Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 1999; 20: 349-354.
361. Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, Rasmussen HH, Orntoft TF, Hein B, Wolf H, Celis A. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res 1999; 59: 3003-3009.
362. Celis JE, Wolf H, Ostergaard M. Bladder squamous cell carcinoma biomarkers derived from proteomics. Electrophoresis 2000; 21: 2115-2121.
363. Celis JE, Celis P, Palsdottir H, Ostergaard M, Gromov P, Primdahl H, Orntoft TF, Wolf H, Celis A, Gromova I. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics 2002; 1: 269-279.
364. Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Yoshimura K, Terai A, Arai Y, Yoshiki T. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 2004; 50: 857-866.
365. Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004; 95: 955-961.
366. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright Jr, GL, Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158: 1491-1502.
367. Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, Lu Y. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 2005; 47: 456-462.
368. Vlahou A, Giannopoulos A, Gregory BW, Manousakas T, Kondylis FI, Wilson LL, Schellhammer PF, Wright GL, Jr. Semmes OJ. Protein profiling in urine for the diagnosis of bladder cancer. Clin Chem 2004; 50: 1438-1441.
369. Sifri R, Gangadharappa S, Acheson LS. Identifying and testing for hereditary susceptibility to common cancers. CA Cancer J Clin 2004; 54: 309-326.
370. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22: 2328-2335.
371. Cipollini G, Tommasi S, Paradiso A, Aretini P, Bonatti F, Brunetti I, Bruno M, Lombardi G, Schittulli F, Sensi E, Tancredi M, Bevilacqua G, Caligo MA. Genetic alterations in hereditary breast cancer. Ann Oncol 2004; 15(Suppl 1): I7-I13.
372. Lynch HT, Casey MJ. Current status of prophylactic surgery for hereditary breast and gynecologic cancers. Curr Opin Obstet Gynecol 2001; 13: 25-30.
373. Sowter H, Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 2005; 26: 1651-1656.
374. Strate LL, Syngal S. Hereditary colorectal cancer syndromes. Cancer Causes Control 2005; 16: 201-213.
375. Venesio T, Molatore S, Cattaneo F, Arrigoni A, Risio M, Ranzani GN. High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis. Gastroenterology 2004; 126: 1681-1685.
376. Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer 2004; 4: 153-158.
377. Bonk T, Humeny A, Sutter C, Gebert J, von Knebel Doeberitz M, Becker CM. Molecular diagnosis of familial adenomatous polyposis (FAP): genotyping of adenomatous polyposis coli (APC) alleles by MALDI-TOF mass spectrometry. Clin Biochem 2002; 35: 87-92.
378. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
379. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
380. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC, Jr. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000; 89: 826-833.
381. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
382. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.
383. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.
384. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v.
385. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892-2899.
386. Hao SP, Tsang NM, Chang KP. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 (LMP-1) gene with nasopharyngeal swabs. Cancer 2003; 97: 1909-1913.
387. Hao SP, Tsang NM, Chang KP. Monitoring tumor recurrence with nasopharyngeal swab and latent membrane protein-1 and epstein-barr nuclear antigen-1 gene detection in treated patients with nasopharyngeal carcinoma. Laryngoscope 2004; 114: 2027-2030.
388. Fan H, Nicholls J, Chua D, Chan KH, Sham J, Lee S, Gulley ML. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 2004; 112: 1036-1041.
389. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-1061.
390. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS. Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 2002; 18: 405-412.
391. Tan PK, Downey TJ, Spitznagel EL, Jr, Xu P, Fu D, Dimitrov DS, Lempicki RA, Raaka BM, Cam MC. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003; 31: 5676-5684.
392. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. Nat Methods 2005; 2: 337-344.
393. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, Geoghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martinez-Murillo F, Morsberger L, Lee H, Petersen D, Quackenbush J, Scott A, Wilson M, Yang Y, Ye SQ, Yu W. Multiple-laboratory comparison of microarray platforms. Nat Methods 2005; 2: 345-350.
394. Members of the Toxicogenomics Research Consortium. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2005; 2: 351-356.
395. Ulivi P, Zoli W, Calistri D, Fabbri F, Tesei A, Rosetti M, Mengozzi M, Amadori, D. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 2006; 206: 611-615.
396. Castaldo G, Tomaiuolo R, Sanduzzi A, Bocchino ML, Ponticiello A, Barra E, Vitale D, Bariffi F, Sacchetti L, Salvatore F. Lung cancer metastatic cells detected in blood by reverse transcriptase-polymerase chain reaction and dot-blot analysis. J Clin Oncol 1997; 15: 3388-3393.
397. Lacroix J, Becker HD, Woerner SM, Rittgen W, Drings P. von Knebel Doeberitz, M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. Int J Cancer 2001; 92: 1-8.
398. Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994; 54: 2136-2140.
399. Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuronspecific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005; 128: 2298-2303.
400. Taback B, Giuliano AE, Hansen NM, Hoon DS. Microsatellite alterations detected in the serum of early stage breast cancer patients. Ann NY Acad Sci 2001; 945: 22-30.
401. Taback B, Giuliano AE, Hansen NM, Singer FR, Shu S, Hoon DS. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. Cancer Res 2003; 63: 1884-1887.
402. Martin KJ, Graner E, Li Y, Price LM, Kritzman BM, Fournier MV, Rhei E, Pardee AB. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci USA 2001; 98: 2646-2651.
403. Bernstein JL, Godbold JH, Raptis G, Watson MA, Levinson B, Aaronson SA, Fleming TP. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res 2005; 11: 6528-6535.
404. Rengucci C, Maiolo P, Saragoni L, Zoli W, Amadori D, Calistri D. Multiple detection of genetic alterations in tumors and stool. Clin Cancer Res 2001; 7: 590-593.
405. Calistri D, Rengucci C, Lattuneddu A, Francioni G, Polifemo AM, Nanni O, Saragoni L, Monti F, Ravaioli A, Zoli W, Amadori D. Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool. Neoplasia 2004; 6: 536-540.
406. Lagerholm S, Lagerholm S, Dutta S, Nair P. Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer. Scand J Gastroenterol 2005; 40: 1343-1350.
407. Botchkina GI, Kim RH, Botchkina IL, Kirshenbaum A, Frischer Z, Adler HL. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin Cancer Res 2005; 11: 3243-3249.
408. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL, Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-3614.
409. von Knobloch R, Brandt H, Hofmann R. Molecular serological diagnosis in transitional cell bladder cancer. Ann NY Acad Sci 2004; 1022: 70-75.
410. Chan MW, Chan LW, Tang NL, Lo KW, Tong JH, Chan AW, Cheung HY, Wong WS, Chan PS, Lai FM, To KF. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003; 104: 611-616.
411. Fujii Y, Kageyama Y, Kawakami S, Kihara K, Oshima H. Detection of disseminated urothelial cancer cells in peripheral venous blood by a cytokeratin 20-specific nested reverse transcriptase-polymerase chain reaction. Jpn J Cancer Res 1999; 90: 753-757.
412. Gudemann CJ, Weitz J, Kienle P, Lacroix J, Wiesel MJ, Soder M, Benner A, Staehler G, Doeberitz MV. Detection of hematogenous micrometastasis in patients with transitional cell carcinoma. J Urol 2000; 164: 532-536.
413. Gazzaniga P, Gandini O, Giuliani L, Magnanti M, Gradilone A, Silvestri I, Gianni W, Gallucci M, Frati L, Agliano AM. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. Clin Cancer Res 2001; 7: 577-583.